BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.71 Million EUR | 20.44% |
| 2022 | -6.88 Million EUR | 12.05% |
| 2021 | -7.83 Million EUR | 1.93% |
| 2020 | -7.98 Million EUR | -41.32% |
| 2019 | -5.65 Million EUR | 43.72% |
| 2018 | -10.04 Million EUR | -7.12% |
| 2017 | -9.37 Million EUR | 32.13% |
| 2016 | -13.81 Million EUR | -202.05% |
| 2015 | -4.57 Million EUR | 7.52% |
| 2014 | -4.94 Million EUR | -12.66% |
| 2013 | -4.38 Million EUR | 22.6% |
| 2012 | -5.66 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.14 Million EUR | 41.11% |
| 2024 Q1 | -2.06 Million EUR | -296.36% |
| 2024 Q2 | -3.64 Million EUR | -76.37% |
| 2023 Q1 | -1.99 Million EUR | -1578.15% |
| 2023 Q4 | -522 Thousand EUR | 62.55% |
| 2023 FY | -5.48 Million EUR | 20.44% |
| 2023 Q3 | -1.39 Million EUR | 22.04% |
| 2023 Q2 | -1.78 Million EUR | 10.47% |
| 2022 Q2 | -1.37 Million EUR | 26.91% |
| 2022 FY | -6.88 Million EUR | 12.05% |
| 2022 Q4 | -119 Thousand EUR | 94.21% |
| 2022 Q3 | -2.05 Million EUR | -49.31% |
| 2022 Q1 | -1.88 Million EUR | -22.34% |
| 2021 Q1 | -2.49 Million EUR | 47.18% |
| 2021 FY | -7.83 Million EUR | 1.93% |
| 2021 Q2 | -960 Thousand EUR | 61.48% |
| 2021 Q4 | -1.54 Million EUR | 1.03% |
| 2021 Q3 | -1.55 Million EUR | -62.08% |
| 2020 Q4 | -4.71 Million EUR | -423.06% |
| 2020 Q1 | -1.18 Million EUR | -22.65% |
| 2020 Q3 | -902 Thousand EUR | 36.57% |
| 2020 Q2 | -1.42 Million EUR | -19.9% |
| 2020 FY | -7.98 Million EUR | -41.32% |
| 2019 FY | -5.65 Million EUR | 43.72% |
| 2019 Q4 | -967 Thousand EUR | 67.77% |
| 2019 Q3 | -3 Million EUR | -26.8% |
| 2019 Q1 | -839 Thousand EUR | 71.21% |
| 2019 Q2 | -2.36 Million EUR | -182.0% |
| 2018 Q2 | -2.4 Million EUR | -13.11% |
| 2018 FY | -10.04 Million EUR | -7.12% |
| 2018 Q4 | -2.91 Million EUR | -29.92% |
| 2018 Q3 | -2.24 Million EUR | 6.81% |
| 2018 Q1 | -2.12 Million EUR | -4.88% |
| 2017 Q3 | -1.71 Million EUR | -42.11% |
| 2017 Q1 | -4.43 Million EUR | 27.72% |
| 2017 Q2 | -1.2 Million EUR | 72.82% |
| 2017 FY | -9.37 Million EUR | 32.13% |
| 2017 Q4 | -2.02 Million EUR | -18.59% |
| 2016 Q4 | -6.12 Million EUR | -154.15% |
| 2016 FY | -13.81 Million EUR | -202.05% |
| 2016 Q3 | -2.41 Million EUR | 23.65% |
| 2016 Q2 | -3.15 Million EUR | -49.54% |
| 2016 Q1 | -2.11 Million EUR | -196.73% |
| 2015 Q1 | -547.21 Thousand EUR | 0.0% |
| 2015 FY | -4.57 Million EUR | 7.52% |
| 2015 Q2 | -1.55 Million EUR | -183.62% |
| 2015 Q3 | -1.76 Million EUR | -13.51% |
| 2015 Q4 | -711.8 Thousand EUR | 59.59% |
| 2014 FY | -4.94 Million EUR | -12.66% |
| 2013 FY | -4.38 Million EUR | 22.6% |
| 2012 FY | -5.66 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 100.973% |
| CureVac N.V. | -274.2 Million EUR | 97.551% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 104.679% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 104.679% |
| Formycon AG | -369 Thousand EUR | -1719.783% |
| Heidelberg Pharma AG | -21.2 Million EUR | 68.34% |
| Medigene AG | -16.14 Million EUR | 58.418% |